NMSC Immunotherapy Guide IAR — ASO

By Med Learning Group on AppTrack Ninja.

In nonmelanoma skin cancer (NMSC), particularly cutaneous squamous cell carcinoma (cSCC), treatment selection has evolved with the integration of immune checkpoint inhibitors (ICIs) across multiple stages of disease. Current guidelines support a risk-adapted approach in which ICIs play a central role for patients with high-risk, locally advanced, or metastatic disease, as well as an emerging role in earlier treatment settings. For unresectable or metastatic disease, ICIs targeting the PD-1/PD-L1 pathway are the preferred systemic therapy, offering durable responses and a favorable tolerabilit…

Categories: Medical, Education

Keyword visibility, ranked search terms and daily position movement for NMSC Immunotherapy Guide IAR.